To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | 216974-75-3 |
| pH value: | Corresponds to reference standard： PASS |
| Non-reduced CE-SDS: | 98.9% |
| SEC-HPLC: | 99.4% |
| Isoelectric Point: | Corresponds to reference standard:PASS |
| Bacterial Endotoxins Test: | ＜1 EU/ml |
| Exogenous Residual DNA: | ＜1 pg/mg |
| Residual protein A: | ＜1 ng/mg |
| Biological Activity: | Compared with standard, the range of biological activity is 113% |
| Osmolality: | Corresponds to reference standard: PASS |
| Peptide mapping: | Corresponds to reference standard: PASS |
| N-terminal sequence: | Corresponds to reference standard:PASS |
| Description: | Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2]. |
| In Vitro: | Bevacizumab-loaded hydrogel results in significant tumor reduction. Bevacizumab is taken up by other organs, including the heart, lung, and spleen. Bevacizumab accumulates higher within tumors via Bevacizumab-loaded hydrogel administration from 14 days onward as compared to the solution formulation. Bevacizumab (I.v.) solution, a typical drug clearance profile is observed where the antibody is cleared from the circulatory system with a half-life of ~4~5 days. The Bevacizumab-loaded hydrogel and the weekly administration of Bevacizumab solution inhibits tumor growth/metastasis in the peritoneal cavity, while one-time i.v. injection of Bevacizumab solution does not provide any therapeutic effect, leading to extensive tumor metastasis[2]. |
| References: | [1]. Liu W, et al. Effect of Avastin on the migration and invasion of pterygium fibroblasts. Eye Sci. 2014;29(4):214-218. [2]. Lee AL, et al. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer. Biomacromolecules. 2015;16(2):465-475. |